The Japan Antibody Therapeutics Market was valued at $7340 Million in 2026 and projected to reach to $10960 Million by 2031, representing a compound annual growth rate of 4.6%. Japan's antibody therapeutics market is positioned for steady growth through 2031, driven by demographic shifts and increased healthcare investment.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Japan's rapidly aging demographic, with over 29% of the population aged 65+, is significantly increasing the prevalence of chronic diseases such as cancer, rheumatoid arthritis, and autoimmune disorders, creating sustained demand for antibody therapeutics.
Japan's advanced healthcare system, coupled with high healthcare spending and universal insurance coverage, enables rapid adoption of innovative biopharmaceutical therapies and supports market expansion for antibody-based treatments.
Japan's Pharmaceuticals and Medical Devices Agency (PMDA) maintains streamlined approval pathways for biologics, including priority review designations, facilitating faster market entry for novel antibody therapeutics compared to other regions.
With a CAGR of 4.6% from 2026 to 2031, Japan's antibody therapeutics market is projected to grow from $7,340 million to $10,960 million, reflecting steady expansion despite lower growth rates compared to the global market's 7.5% CAGR.
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
Administered teclistamab, a BCMA×CD3 bispecific antibody for relapsed/refractory multiple myeloma, using a hospital-based step-up dosing model. | Supports safe administration of complex bispecific antibodies, reduces serious toxicity risk through specialist monitoring, and creates a practical hospital-to-clinic care pathway for high-value antibody therapeutics. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | PIPELINE PRODUCTS (Product) |
| Forecast Period | 2026-2031 |
| Growth Rate | CAGR of 7.5% from 2026 to 2031 |
| Largest Segment | COMMERCIALIZED PRODUCTS (Product) |
| Market Size Base Year (Billions) | ~USD 311.44 (2026) |
| Revenue Forecast (Billions) | ~USD 447.11 (2031) |
| Segments Covered | Product, Type, Format, Payload Type, Target, Source, Route Of Administration, Therapeutic Area, End User |
9 segment dimensions are covered across the global market.
Japan's antibody therapeutics market is valued at $7,340 million in 2026 and is expected to reach $10,960 million by 2031.
Japan's antibody therapeutics market is projected to grow at a compound annual growth rate (CAGR) of 4.6% from 2026 to 2031.
Key growth drivers in Japan include an aging population, rising prevalence of chronic diseases, increased healthcare spending, strong regulatory support, and active investment in biopharmaceutical research and development.
Oncology and immunology represent the most significant therapeutic areas in Japan's antibody therapeutics market, with substantial clinical development and commercial activity.
Japan maintains one of the most mature and well-regulated antibody therapeutics markets in Asia Pacific, with strong manufacturing capabilities, high healthcare spending, and robust pharmaceutical innovation infrastructure.
This research study extensively used secondary sources, directories, and databases to identify and collect valuable information for analyzing the global antibody therapeutics market. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with primary research inputs to arrive at the final market size.
Secondary research was used primarily to identify and collect information for the extensive, technical, market-oriented, and commercial study. The secondary sources used for this study include annual reports, SEC filings, investor presentations, the World Health Organization (WHO), the United States Food and Drug Administration (US FDA), the National Center for Biotechnology Information (NCBI), and regulatory body websites, among others. These sources also provided key information on major players, market classification, and segmentation aligned with industry trends, regional and country-level markets, market developments, and technology perspectives.
In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market's prospects. Primary sources from both the supply and demand sides of the market were interviewed to gather qualitative and quantitative information. The following is a breakdown of the primary respondents:

To know about the assumptions considered for the study, download the pdf brochure
Both top-down and bottom-up approaches were used to estimate and validate the total size of the antibody therapeutics market. These methods were also used extensively to estimate the size of various market subsegments. The research methodology used to estimate the market size includes the following:

After determining the overall market size through the estimation process, the total market was segmented into several segments and subsegments. Where applicable, data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from both the demand and supply sides.
Therapeutic antibodies are targeted biopharmaceuticals that trigger a biological response. Therapeutic antibodies are drugs that use antibodies, which play a significant role in the body's innate immune system. Antibodies are produced by B cells, a type of immune cell, to attack foreign substances (antigens) in response to infections or allergens. Since antibodies recognize and attack only specific antigens, these properties are leveraged to generate genetically engineered antibodies (chimeric, humanized, fully human, engineered fragments & bispecific) designed to target and neutralize specific disease markers.
With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:
Full forecast, segment splits, and company analysis for all Antibody Therapeutics Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report